Shenzhen Longyao Biological

Longyao Biological is a clinical-stage biotechnology company headquartered in Shenzhen, China, specializing in the development of next-generation immune cell therapies for cancer. The company utilizes its proprietary costimulatory signal platforms, most notably its OX40-enhanced CAR-T technology, to improve the expansion, persistence, and anti-tumor activity of engineered T cells. Its lead candidate, LY007, is a CD20-targeted CAR-T therapy currently in Phase 1/2 clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Beyond hematological malignancies, Longyao is also advancing a pipeline of multi-target CAR-T and TCR-T therapies aimed at addressing the challenges of treating solid tumors.